New pill shows promise against tough breast cancers
NCT ID NCT03624543
First seen Jan 30, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The drug is taken by mouth in 28-day cycles. The main goal is to see if the drug can shrink tumors. Researchers will also track side effects and study tumor samples to understand how the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CFI-400945 (a drug taken by mouth)
What this could lead to
If it works, this could offer a new treatment option to shrink tumors and control advanced breast cancer that has not responded to standard chemotherapy.
What could go wrong
This is a small, early-phase trial (51 people) with no comparison group, so results may not apply broadly. The drug may cause side effects and may not shrink tumors in all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.